



*For immediate release 2.00pm: 24 May 2017*

**HVIVO PLC**  
("hVIVO" or the "Company")

**Result of Annual General Meeting**

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 24 May 2017, were duly passed.

**For further information please contact:**

**hVIVO plc** +44 207 756 1300  
Kym Denny (Chief Executive Officer)  
Graham Yeatman (Chief Financial & Business Officer)

**Numis Securities Limited** +44 207 260 1000  
Michael Meade / Freddie Barnfield (Nominated Adviser)  
James Black / Michael Burke (Corporate Broking)

**FTI Consulting**  
Simon Conway / Victoria Foster Mitchell (UK) +44 203 727 1000  
John Capodanno / Evan Smith (US) +1 212 850 5705

**Notes to Editors:**

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.